Drug Trial Radar · NCT05643638
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
65
Actual
Start
Mar 4, 2024
Primary completion
Mar 17, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Cynata Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.
Conditions
- Graft Versus Host Disease, Acute
Interventions
CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)Biological
Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
PlaceboBiological
The placebo product is identical to CYP-001, except that it contains no active agent
CorticosteroidsDrug
All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: 28 days
Locations
39 sites in 7 countries. Site status is shown where the registry gives one.
Banner MD Anderson
Phoenix, Arizona
Mayo Clinic Hospital
Phoenix, Arizona
University of Arkansas Medical Center
Little Rock, Arkansas
Mayo Clinic Hospital
Jacksonville, Florida
Memorial healthcare System
Pembroke Pines, Florida
BMT Group of Georgia
Atlanta, Georgia
Northwestern University
Evanston, Illinois
Karmanos Cancer Institute
Detroit, Michigan
University Of Nebrasaka Medical Center
Omaha, Nebraska
Weill Cornell Medicine - New York Presbyterian Hospital
New York, New York
Cleveland Clinic
Cleveland, Ohio
Penn State Health
Hershey, Pennsylvania
University of Utah
Salt Lake City, Utah
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Hospital Claude Huriez
Lille, France
Hôpital Necker Enfants Malades
Paris, France
Hôpital Universitaire Pitié-Salpêtrière
Paris, France
Azienda Ospedaliero Universitaria delle Marche
Ancona, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Istituto Clinico Humanitas
Rozzano, Italy
IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
Ospedale dell'Angelo di Mestre
Venezia, Italy
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitato De La Princesa
Madrid, Spain
Hospital Universitario Virgen de la Arrixaca
Murcia, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Anadolu Medical Center
Eskişehir, Turkey (Türkiye)
Gayrettepe Florence Nightingale Hastanesi
Istanbul, Turkey (Türkiye)
Koc University
Istanbul, Turkey (Türkiye)
Memorial Bahcelievler Hospital
Istanbul, Turkey (Türkiye)
Izmir Medicalpark Hospital
Izmir, Turkey (Türkiye)
İnonu University
Malatya, Turkey (Türkiye)
Dr Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
Yenimahalle, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.